GSK and NIH Initiative to Develop Long-Acting HIV Treatment and Prevention Tools

Partnership objectives:

  1. Develop new approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs).
  2. Create viable alternatives for people who are at substantial risk for HIV infection and for infected individuals for whom adherence is an impediment to effective treatment.
  3. Provide new treatments for people living with HIV.

The partnership specifically enables researchers to develop one or more broadly neutralizing antibodies (bNAbs), which can stop a wide range of HIV strains from infecting human cells in the laboratory, into a product to treat or prevent HIV infection. The partnership specifically enables researchers to develop one or more broadly neutralizing antibodies (bNAbs), which can stop a wide range of HIV strains from infecting human cells in the laboratory, into a product to treat or prevent HIV infection. Copyright Photo Credits: GSK

What are the health needs and challenges?

Effective methods of treating and preventing HIV with antiretroviral drugs are available today. However, they currently require that people take medication every day, which is challenging for many individuals. People living with HIV need additional treatment options. By working to develop preventive and therapeutic medicines that can be taken much less often, this partnership aims to create viable alternatives for people who are at substantial risk for HIV infection or for infected individuals for whom adherence is an impediment to effective treatment. 

Description of partnership activities and how they address needs and challenges

Established between the National Institute of Allergy and Infectious Diseases (NIAID), and GlaxoSmithKline (GSK), the partnership specifically enables researchers to develop one or more broadly neutralizing antibodies (bNAbs), which can stop a wide range of HIV strains from infecting human cells in the laboratory, into a product to treat or prevent HIV infection.

Research and development will be conducted by NIAID’s Dale and Betty Bumpers Vaccine Research Center (VRC) scientists under a five-year cooperative research and development agreement with GSK. This will combine the scientists expertise in discovering and analyzing HIV bNAbs with the company’s pharmaceutical development capability and experience in long-acting antiretroviral therapies.

The program will be aimed to evaluate and work to improve known and novel HIV bNAbs, and identify combinations of bNAbs capable of blocking the widest range of HIV strains. The joint team will evaluate bNAbs discovered at NIAID to determine which ones are the most promising for further development. Ultimately, the research team expects to combine two complementary antibodies, each targeting different sites on the HIV surface molecule that attaches to human cells. Virus strains that are resistant to one bNAb likely would be vulnerable to the other, increasing the likelihood that at least one of the two antibodies neutralizes the virus. 

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) National Institute of Allergy and Infectious Diseases (NIAID)

Type of Partner(s) Other Business

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Research & Development - Development of Treatments

Targeted Population(s) General population, Patients in needs of treatment, People with low income

Region(s) North America

Number of Countries 1

Country(ies) United States of America

Start Date 2015

More information Press Release

Completed date 2020

« This partnership unites two organizations with more than three decades of experience fighting HIV. We are thrilled to partner with NIAID to rapidly translate the VRC’s science into innovative medicines. »

Zhi Hong, Ph.D., senior vice president for infectious diseases at GSK